Sue Friedman
Image by courtesy of force
Diagnosed at 33, Sue Friedman had already undergone treatment when she found out about the BRCA2 mutation that had given her a 9-in-10 chance of developing hereditary breast cancer.
Three years later, in 1999, Friedman founded FORCE: Facing Our Risk of Cancer Empowered, an organization advocating for awareness of hereditary breast and ovarian cancers. And they’ve had a pretty big year.
In April, the Supreme Court heard arguments about whether Myriad Genetics, Inc. had the right to patent the BRCA1 and BRCA2 genes. What seemed like an obscure matter was a life and death issue for many Ashkenazi women who, like Friedman, are far more likely to carry the mutation than the general population.
Friedman wrote an amicus brief to the court, expressing her concern at the implications of Myriad’s monopoly over the genes. Tests would be more expensive, and less accessible, she argued, because of the company’s control over research.
Then, in May, Angelina Jolie came out with a revelation in the opinion pages of the New York Times: After testing positive for a BRCA1 gene mutation, she had opted for a double mastectomy.
For activists like Friedman, 50, this was a long-awaited chance to bring attention to a health risk that she and others had been facing in silence and, mostly, alone.
Partly as a result of Friedman’s efforts, FORCE’s 15th anniversary will be a happy one: In June, the Supreme Court ruled that human DNA cannot be patented without being altered in some way, a victory for BRCA positive women.
A message from our CEO & publisher Rachel Fishman Feddersen
I hope you appreciated this article. Before you move on, I wanted to ask you to support the Forward’s award-winning journalism during our High Holiday Monthly Donor Drive.
If you’ve turned to the Forward in the past 12 months to better understand the world around you, we hope you will support us with a gift now. Your support has a direct impact, giving us the resources we need to report from Israel and around the U.S., across college campuses, and wherever there is news of importance to American Jews.
Make a monthly or one-time gift and support Jewish journalism throughout 5785. The first six months of your monthly gift will be matched for twice the investment in independent Jewish journalism.
— Rachel Fishman Feddersen, Publisher and CEO
